Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The medication is administered as a once-weekly subcutaneous injection and is currently in phase 3 clinical trials, with FDA approval potentially on the horizon pending trial outcomes
Some states include anti-obesity medications in their Medicaid formularies while others explicitly exclude them
Understanding how these three signalling axes interact is central to current metabolic research and forms the primary basis for ongoing investigational study of this compound
Appetite control becomes more pronounced, portion sizes decrease naturally, and cravings for high-calorie foods diminish
Moreover, partnerships between e-pharmacy platforms and drug manufacturers in 2025 have accelerated the availability of oral GLP-1 therapies across wider geographies
Design Phase 3, double-blind, randomised, placebo-controlled Duration 72 weeks (20-week titration + 52-week maintenance) Arms Tirzepatide 5 mg, 10 mg, 15 mg, placebo (1:1:1:1) Lifestyle All arms received counselling on diet and physical activity Sponsor Eli Lilly & Company Reference Jastreboff AM et al
US$ 29.96
US$ 28.82
US$ 27.59
US$ 20.34
US$ 21.23
US$ 27.61
US$ 26.13
